Sigilon Therapeutics is developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon's therapeutics consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon's Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/17/20 | $80,300,000 | Series B |
BlackRock Canada Pension Plan Investment Board Eli Lilly and Company Flagship Pioneering Longevity Vision Fund | undisclosed |
